英文字典中文字典Word104.com



中文字典辭典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z   







請輸入英文單字,中文詞皆可:

hermetical    
a. 密封的;神密的

密封的;神密的

Hermetic \Her*met"ic\, Hermetical \Her*met"ic*al\, a. [F.
herm['e]tique. See Note under {Hermes}, 1.]
1. Of, pertaining to, or taught by, Hermes Trismegistus; as,
hermetic philosophy. Hence: Alchemical; chemic. "Delusions
of the hermetic art." --Burke.
[1913 Webster]

The alchemists, as the people were called who tried
to make gold, considered themselves followers of
Hermes, and often called themselves Hermetic
philosophers. --A. B.
Buckley.
[1913 Webster]

2. Of or pertaining to the system which explains the causes
of diseases and the operations of medicine on the
principles of the hermetic philosophy, and which made much
use, as a remedy, of an alkali and an acid; as, hermetic
medicine.
[1913 Webster]

3. Made perfectly close or air-tight by fusion, so that no
gas or spirit can enter or escape; as, an hermetic seal.
See Note under {Hermetically}.
[1913 Webster]

{Hermetic art}, alchemy.

{Hermetic books}.
(a) Books of the Egyptians, which treat of astrology.
(b) Books which treat of universal principles, of the
nature and orders of celestial beings, of medicine,
and other topics.
[1913 Webster]

請選擇你想看的字典辭典:
單詞字典翻譯
Hermetical查看 Hermetical 在Google字典中的解釋Google英翻中〔查看〕
Hermetical查看 Hermetical 在Yahoo字典中的解釋Yahoo英翻中〔查看〕





安裝中文字典英文字典查詢工具!


中文字典英文字典工具:
選擇顏色:
輸入中英文單字

































































英文字典中文字典相關資料:
  • SGLT2 inhibitors for non-diabetic kidney disease: drugs to . . .
    SGLT2 INHIBITORS IMPROVE CV OUTCOMES ALSO IN NON-DIABETIC PATIENTS WITH HF The first large Phase 3 trial of SGLT2 inhibitors enrolling non-diabetic patients in addition to diabetics was the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial
  • SGLT2 Inhibitors Use in Non-Diabetic Patients: A Narrative Review
    While the SGLT-2 inhibitors are not the drug of choice as the first-line treatment for DM, current research has elucidated that patients with various existing conditions have shown proven benefits on their comorbidities but not on their respective diabetic profiles
  • Comparison of Effectiveness Among Different Sodium‐Glucose . . .
    In patients with chronic kidney disease, there were no differences in the efficacy outcomes among SGLT2 inhibitors, while in patients without chronic kidney disease, empagliflozin was associated with lower risk of the primary outcome compared with ertugliflozin (HR, 0 77 [95% CI, 0 60–0 98])
  • SGLT2 Inhibitors Improve All-Cause and Cardiovascular . . . - AAFP
    What effect do sodium-glucose cotransporter-2 (SGLT2) inhibitors have on mortality and cardiovascular and renal outcomes in patients with and without diabetes mellitus, heart failure, or
  • SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals . . .
    The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and or CKD This review may shed light on the use of SGLT2 inhibitors in conditions such as stage A HF and metabolic syndrome
  • Sodium-glucose cotransporter-2 inhibitors in non-diabetic . . .
    In patients with diabetes mellitus treated using SGLT2 inhibitors, increased risk of euglycaemic ketoacidosis has been described in various clinical situations, including in the perioperative setting 1,2 In this context, it remains unclear whether patients without diabetes mellitus treated with SGLT2 inhibitors can also develop euglycaemic keto
  • SGLT2 inhibitors: Beyond glycemic control - ScienceDirect
    Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM)





中文字典-英文字典  2005-2009

|中文姓名英譯,姓名翻譯 |简体中文英文字典